CheckMate-577
2021
Adjuvant Nivolumab in Resected Oesophageal/GEJ Cancer
In 794 patients with resected oesophageal/GEJ cancer and residual pathologic disease after neoadjuvant chemoradiation, adjuvant nivolumab for one year improved disease-free survival compared with placebo.
Result
Efficacy: Disease-free survivalHR 0.69
Below 1 favours nivolumab for one year, above 1 favours placebo.
Event rates Nivolumab for one year 22.4 vs placebo 11.0 months
Also reported: Final OS 51.7 vs 35.3 months (HR 0.85; p=0.1064), not statistically significant.
- Subtopic
- Oesophageal adjuvant
- Design
- Double-blind RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Kelly RJ, et al. N Engl J Med. 2021;384(13):1191-1203.doi 10.1056/NEJMoa2032125
Discussion & critique
DFS-positive but OS-not-significant: a recurrent pattern in adjuvant immunotherapy trials. Counsel patients accordingly.